Introduction to TCR


The TCR-T technology works by genetically modifying T cells to redirect their cytotoxic activity towards tumor associated antigens (TAA). This modification features enhanced T cell to target cell affinity as well as specificity, therefore also being called “Affinity-Enhanced TCR”.

TCR is composed of two subunits TCRα and TCRβ. Each TCR subunit contains an antigen-recognition domain. When a TCR recognizes a compatible peptide-MHC complex presented by a target cell, it elicits activation signals to T cells and initiates target cell killing.


Mechanism of TCR-T


Proteins inside cancer cells can undergo degradation, processing and antigen presentation and finally display on cell surface. The MHC presented cancer antigen can therefore be recognized by TCR-T cells, which secrete cytolytic components to mediate cancer cell clearance.


Advantages of TCR-T therapy


Broad selection of cancer-specific antigens

Although CAR-T therapy demonstrated tremendous success in hematopoietic cancers, its efficacy in solid cancers remain elusive. One prominent drawback of CAR-T cells is the lack of target antigens. TCR-T cells can be engineered to target majority of TAAs, especially ones located intracellularly. Thus, the application of TCR-T therapy outcompetes antibody therapy and CAR-T therapy. TCR-T cells are also capable of distinguishing mutated antigens, which enables extraordinary selectivity towards tumor tissues while sparing normal tissues.


Humanized for long-term protection

Typically, therapeutic antibody or the chimeric receptors in CAR-T cells are derived from rodent immunization. Direct use of these antibodies often lead to the development of anti-drug-antibodies in patients, which limits the duration of antibody or CAR-T cells. The TCR constructs in TCR-T cells, however, are derived from patients’ autologous TCR repertoire. They are fully humanized and do not lead to rejection responses, which allows for long-term protection by TCR-T cells.



                             Disadvantages of CAR-T                                                                                         Advantages of TCR-T



Floor 4, Building 6, 8 shengmingyuan Rd., Lifescience park, Changping

District, Beijing, China


No.101 5-10-2 Cuibo Road, Chunhui Street,Dadukou District, Chongqing

Contact us

© 2017 Chongqing TCRCure Biological Technology Co Ltd. All Rights Reserved.  渝ICP备17005995号  Powered by: www.300.cnManager